256504-39-9

Basic information

• Product Name: ethyl 5-aMino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate
• Synonyms: ethyl 5-aMino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate;5-Amino-1-[(2-fluorophenyl)methyl]-1H-pyrazole-3-carboxylic acid ethyl ester
• CAS NO: 256504-39-9
• Molecular Formula: C₁₃H₁₄FN₃O₂
• Molecular Weight: 263.2675632
• EINECS: -0
• Product Categories: Riociguat
• Mol File: 256504-39-9.mol

Chemical Properties

• Boiling Point: 451.9±40.0 °C(Predicted)
• Appearance: /
• Density: 1.29±0.1 g/cm3(Predicted)
• Vapor Pressure: 0Pa at 20℃
• PKA: 1.50±0.10(Predicted)
• CAS DataBase Reference: ethyl 5-aMino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-aMino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate(256504-39-9)
• EPA Substance Registry System: ethyl 5-aMino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate(256504-39-9)

Safety Data

• Hazardous Substances Data: 256504-39-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
Ethyl 5-Amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate is used as a research compound for the development of new drugs targeting soluble guanylate cyclase. This enzyme plays a crucial role in the regulation of vascular tone and blood flow, making it a potential therapeutic target for conditions such as hypertension, heart failure, and pulmonary hypertension.
Used in Soluble Guanylate Cyclase Stimulation Studies:
In the field of biomedical research, ethyl 5-Amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate is used as a stimulator of soluble guanylate cyclase for investigating its potential effects on cellular signaling pathways and physiological responses. This application aids in understanding the underlying mechanisms of various diseases and the development of novel therapeutic strategies.
Used in Drug Development for Cardiovascular Diseases:
Ethyl 5-Amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate is utilized as a key compound in the development of drugs aimed at treating cardiovascular diseases. By stimulating soluble guanylate cyclase, it may help in the regulation of blood vessel dilation and overall cardiovascular function, offering potential benefits for patients suffering from conditions such as hypertension and heart failure.

Upstream product

• 51859-98-4 (2-fluorobenzyl)hydrazine 
• 627076-29-3 sodium salt of ethyl cyanopyruvate 
• 1216246-45-5 (2-fluorobenzyl)hydrazine hydrochloride salt 
• 95-92-1 oxalic acid diethyl ester 
• 75-05-8 acetonitrile 
• 345-35-7 2-fluorobenzyl chloride 

Downstream Products

• 256376-59-7 ethyl 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate 
• 1350653-26-7 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile 
• 1426309-48-9 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide hydrochloride 
• 1361570-05-9 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-7-(2,2,2-trifluoro ethyl)-7,9-dihydro-8H-purin-8-one 
• 1361570-04-8 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-iodo-7-(2,2,2-trifluoro ethyl)-7,9-dihydro-8H-purin-8-one 
• 1361569-39-2 6-amino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-7-(2,2,2-trifluoroethyl)-7,9-dihydro-8H-purin-8-one 
• 1361570-68-4 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidine-4,5-diamine 
• 1361570-67-3 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-nitropyrimidin-4-amine 
• 1361570-66-2 3-(4-chloro-5-nitropyrimidin-2-yl)-5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine 
• 1361570-65-1 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-nitropyrimidin-4-ol 
• 1350653-22-3 methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}(2,2,2-trifluoroethyl)carbamate 
• 1350653-20-1 methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-5-yl}carbamate 
• 1350653-30-3 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidine-4,5,6-triamine 
• 1350653-29-0 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-[(E)-phenyldiazenyl]pyrimidine-4,6-diamine 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF METHYL 4,6-DIAMINO-2-[L-(2-FHIOROBENZVR)-LH-PYRAZOLO I3,4-BLPVRIDIN-3-VN-5-PYRIMIDINYL(METHVL)CARBAMATE AND ITS POLYMORPHS THEREOF

The present invention relates to process for the preparation of methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-lH-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl(methyl)carbamate and its polymorphs thereof compound of formula-1, represented by the following structur

Novel Combination Containing a Stimulator of Soluble Guanylate Cyclase and a Lipid-Lowering Substance

A combination product which comprises as pharmaceutically active ingredients at least one active ingredient component A and at least one active ingredient component B, where active ingredient component A is a direct soluble guanylate cyclase stimulator of

NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES

The invention relates to novel 2,5-disubstituted pyrimidine derivatives, which stimulate the soluble guanylate cyclase, method for production and use thereof for the production of medicaments, in particular medicaments for the treatment of central nervous system diseases.

4-AMINO-SUBSTITUTED PYRIMIDINE DERIVATIVES

The invention relates to novel 4-amino-substituted pyrimidine derivatives, which stimulate soluble guanylate cyclase, method for production and use thereof for the production of medicaments, in particular medicaments for the treatment of diseases of the c

PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVE

The invention relates to a substituted pyrazole derivative and the use thereof as a medicament, particularly as a medicament for treating cardiovascular diseases.

Substituted pyrazole derivatives

The present invention relates to novel substituted pyrazole derivatives of the general formula (I) in which the substituents R1, R2, R3, A, X and Y are each as defined, and to processes for their preparation and to their use as medicaments, in particular as medicaments for the treatment of cardiovascular disorders.

Novel sulfonamide-substituted pyrazolopyridine derivatives

The invention relates to novel pyrazolopyridine derivatives of formula (I) wherein R1 represents H, Cl or NH2, and R2 and R3 form; together with the heteroatoms to which they are bonded, a five to six-membered heterocycle which can be saturated or partially unsaturated, can optionally contain at least one other heteroatom from the group N, O, S and can be optionally substituted. The invention also relates to salts, isomers and hydrates of said derivatives, in the form of stimulators of soluble guanylate cyclase and as agents for treating cardiovascular diseases, hypertonia, thrombo-embolic diseases and ischaemia, sexual dysfunction, inflammations, and diseases of the central nervous system.

Novel carbamate-substituted pyrazolopyridine derivatives

The invention relates to novel pyrazolopyridine derivatives of the formula (I), wherein R1 represents hydrogen or a di-C1-6-alkylaminocarbonyl group, R2 represents a rest of the formula —O—CO—NR3R4, wherein R3 and R4 are the same or different and represen

Substituted pyrazole derivatives condensed with six-membered heterocyclic rings

The present invention relates to novel substituted pyrazole derivatives of the general formula (I) in which R1, R2, R3and A are each as defined, and to processes for their preparation and to their use as medicaments, in pa

Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase.

The pyrazolopyridine stimulators of soluble guanylate cyclase BAY 41-2272 and 41-8543 were oxidised in rats and dogs at their 5-pyrimidinyl-cyclopropyl and -morpholino residue. These metabolites activate the soluble guanylate cyclase, induce vasoelaxation and thereby may contribute to the in vivo activity of BAY 41-2272 and BAY 41-8543.